Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone

Chemical Biology and Drug Design

Volumn 76, Issue 1, 2010, Pages 43-58

  Palmeira, Andreia ^a   Paiva, Ana ^a   Sousa, Emília ^a   Seca, Hugo ^a   Almeida, Gabriela M ^a   Lima, Raquel T ^a   Fernandes, Miguel X ^b   Pinto, Madalena ^a   Vasconcelos, M Helena ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF MADEIRA   (Portugal)

Author keywords

Antiproliferation; Apoptosis; Bcl xL; Leukemia; Structure based screening; Xanthone

Indexed keywords

2 HYDROXYMETHYL 3 (4 HYDROXY 3 METHOXYPHENYL) 1,4 DIOXANE[5,6 C]XANTHONE; 3 [(6' BROMOHEXYL)OXY] 4 HYDROXY 9H XANTHEN 9 ONE; 3,4 BIS(3 METHYLBUT 2 ENYLOXY) 9H XANTHEN 9 ONE; 3,4 DIHYDRO 12 HYDROXY 2,2 DIMETHYL 2H,6H PYRANO[2,3 B]XANTHEN 6 ONE; 3,4 DIHYDROXYXANTHONE; ANTINEOPLASTIC AGENT; BIM PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN BCL XL; PYRANOXANTHONE DERIVATIVE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; XANTHONE DERIVATIVE; PROTEIN BCL X;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN BV 173; CELL STRAIN HL 60; CELL STRAIN K 562; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MOLECULAR DOCKING; PRENYLATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; LEUKEMIA; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA; MODELS, MOLECULAR; XANTHONES;

EID: 77953008434     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00978.x     Document Type: Article

References (62)

1. Pinto M.M., Sousa M.E., Nascimento M.S. (2005) Xanthone derivatives: new insights in biological activities. Curr Med Chem 12 : 2517 2538.
2. Kupchan S.M., Streelman D.R., Sneden A.T. (1980) Psorospermin, a new antileukemic xanthone from Psorospermum febrifugum. J Nat Prod 43 : 296 301.
3. Rewcastle G.W., Atwell G.J., Li Z.A., Baguley B.C., Denny W.A. (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34 : 217 222.
4. Jameson M.B., Thompson P.I., Baguley B.C., Evans B.D., Harvey V.J., Porter D.J., McCrystal M.R., Small M., Bellenger K., Gumbrell L., Halbert G.W., Kestell P. (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone- 4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88 : 1844 1850. (Pubitemid 36829657)
5. Hakim E.H., Asnizar, Yurnawilis, Aimi N., Kitajima M., Takayama H. (2002) Artoindonesianin P, a new prenylated flavone with cytotoxic activity from Artocarpus lanceifolius. Fitoterapia 73 : 668 673.
6. Wu X., Cao S., Goh S., Hsu A., Tan B.K. (2002) Mitochondrial destabilisation and caspase-3 activation are involved in the apoptosis of Jurkat cells induced by gaudichaudione A, a cytotoxic xanthone. Planta Med 68 : 198 203.
7. Elomri A., Mitaku S., Michel S., Skaltsounis A.L., Tillequin F., Koch M., Pierré A., Guilbaud N., Léonce S., Kraus-Berthier L., Rolland Y., Atassi G. (1996) Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series. J Med Chem 39 : 4762 4766.
8. Ghirtis K.P.N., Marakos P., Skaltsounis A.L., Leonce S., Caignard D.H., Atassi G. (2000) Synthesis and Conformational Analysis of Some New Pyrano[2,3-c]xanthen-7-one and Pyrano[3,2-b]xanthen-6-one Derivatives with Cytotoxic Activity. Heterocycles 53 : 93.
9. Kostakis I.K., Magiatis P., Pouli N., Marakos P., Skaltsounis A.L., Pratsinis H., Léonce S., Pierré A. (2002) Design, synthesis, and antiproliferative activity of some new pyrazole-fused amino derivatives of the pyranoxanthenone, pyranothioxanthenone, and pyranoacridone ring systems: a new class of cytotoxic agents. J Med Chem 45 : 2599 2609.
10. Kostakis I.K., Pouli N., Marakos P., Mikros E., Skaltsounis A.L., Leonce S., Atassi G., Renard P. (2001) Synthesis, cytotoxic activity, NMR study and stereochemical effects of some new pyrano[3,2-b]thioxanthen-6-ones and pyrano[2,3-c]thioxanthen-7-ones. Bioorg Med Chem 9 : 2793 2802.
11. Pinto M.M., Sousa E.P. (2003) Natural and synthetic xanthonolignoids: chemistry and biological activities. Curr Med Chem 10 : 1 12.
12. Castanheiro R.A., Pinto M.M., Silva A.M., Cravo S.M., Gales L., Damas A.M., Nazareth N., Nascimento M.S., Eaton G. (2007) Dihydroxyxanthones prenylated derivatives: synthesis, structure elucidation, and growth inhibitory activity on human tumor cell lines with improvement of selectivity for MCF-7. Bioorg Med Chem 15 : 6080 6088.
13. Pinto M.M., Castanheiro R. (2008) Natural prenylated xanthones: chemistry and biological activities. In : Brahmachari G., editor. Natural Products: Chemistry, Biochemistry and Pharmacology.
14. Saraiva L., Fresco P., Pinto E., Sousa E., Pinto M., Goncalves J. (2003) Inhibition of protein kinase C by synthetic xanthone derivatives. Bioorg Med Chem 11 : 1215 1225.
15. Pedro M., Cerqueira F., Sousa M.E., Nascimento M.S., Pinto M. (2002) Xanthones as inhibitors of growth of human cancer cell lines and their effects on the proliferation of human lymphocytes in vitro. Bioorg Med Chem 10 : 3725 3730.
16. Gottlieb O.R.M., Oliveira G.G., Melo M.T. (1970) Xanthones from Kielmeyera speciosa. Phytochemistry 9 : 2537 2544.
17. Sousa E.P., Nazareth N., Gales L., Damas A., Nascimento M.S.J., Pinto M. (2009) Bromoalkoxyxanthones as promising antitumor agents: synthesis, crystal structure and effect on human tumor cell lines. Eur J Med Chem 44 : 1 6.
18. Sambrook J., Fritsch E.F., Maniatis T. (1989) Molecular Cloning: A Laboratory Manual.
19. Lima R.T., Martins L.M., Guimaraes J.E., Sambade C., Vasconcelos M.H. (2004) Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11 : 309 316.
20. Vasconcelos M.H., Beleza S.S., Quirk C., Maia L.F., Sambade C., Guimaraes J.E. (2000) Limited synergistic effect of antisense oligonucleotides against bcr-abl and transferrin receptor mRNA in leukemic cells in culture. Cancer Lett 152 : 135 143.
21. Lima R.T.G., Vasconcelos M.H. (2007) Overcoming K562Dox resistance to STI571 (Gleevec) by downregulation of P-gp expression using siRNAs. Cancer Ther 5 : 67 76.
22. Zsoldos Z., Reid D., Simon A., Sadjad B.S., Johnson A.P. (2006) eHiTS: an innovative approach to the docking and scoring function problems. Curr Protein Pept Sci 7 : 421 435.
23. Zsoldos Z., Reid D., Simon A., Sadjad S.B., Johnson A.P. (2007) eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model 26 : 198 212.
24. Froimowitz M. (1993) HyperChem: a software package for computational chemistry and molecular modeling. BioTechniques 14 : 1010 1013.
25. O'Boyle N.M., Hutchison G.R. (2008) Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit. Chem Cent J 9 : 5.
26. Ordog R. (2008) PyDeT, a PyMOL plug-in for visualizing geometric concepts around proteins. Bioinformation 2 : 346 347.
27. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin TE. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25 : 1605 1612.
28. Castanheiro R.P., Pinto M.M., Cravo S., Pinto D., Silva A., Kijjoa A. (2009) Improved methodologies for synthesis of prenylated xanthones by microwave irradiation and combination of heterogeneous catalysis (K10 clay) with microwave irradiation. Tetrahedron 65 : 3848 3857.
29. Sousa E.P.S., Pinto M.M., Pedro M.M., Cerqueira F.A.M., Nascimento M.S.J. (2002) Isomeric Kielcorins and Dihydroxyxanthones: Synthesis, Structure Elucidation, and Inhibitory Activities of Growth of Human Cancer Cell Lines and on the Proliferation of Human Lymphocytes In Vitro. Helv Chim Acta 85 : 2862 2876.
30. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res 28 : 235 242.
31. Pouli N., Marakos P. (2009) Fused xanthone derivatives as antiproliferative agents. Anticancer Agents Med Chem 9 : 77 98.
32. Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K., Ishikawa F., Takaku F., Yazaki Y., Hirai H. (1992) Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79 : 2378 2383.
33. Gahmberg C.G., Andersson L.C. (1981) K562-a human leukemia cell line with erythroid features. Semin Hematol 18 : 72 77.
34. Law J.C.R., Yalowich J.C., Leder G.H., Ferrell R.E. (1993) Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 17 : 1045 1050.
35. Lima R.T., Martins L.M., Guimarães J.E., Sambade C., Vasconcelos M.H. (2006) Chemosensitization effects of XIAP downregulation in K562 leukemia cells. J Chemother 18 : 98 102.
36. Ghirtis K.P., Marakos P., Skaltsounis A.L., Leonce S., Atassi G., Caignard D.H. (2001) Design and synthesis of some new pyranoxanthenones with cytotoxic activity. J Heterocycl Chem 38 : 147.
37. Gong J.G., Costanzo A., Yang H.Q., Melino G., Kaelin W.G. Jr., Levrero M., Wang J.Y.J. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399 : 806 809.
38. Almeida G.M., Duarte T.L., Farmer P.B., Steward W.P., Jones G.D. (2008) Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer 122 : 1810 1819.
39. Kang S.G., Chung H., Yoo Y.D., Lee J.G., Choi Y.I., Yu Y.S. (2001) Mechanism of growth inhibitory effect of Mitomycin-C on cultured human retinal pigment epithelial cells: apoptosis and cell cycle arrest. Curr Eye Res 22 : 174 181.
40. Yun J., Zhong Q., Kwak J.Y., Lee W.H. (2005) Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene 24 : 4009 4016.
41. Hammond E.M., Green S.L., Giaccia A.J. (2003) Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat Res 532 : 205 213.
42. Zhang G.S., Liu D.S., Dai C.W., Li R.J. (2006) Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol 81 : 242 255.
43. Estrov Z., Shishodia S., Faderl S., Harris D., Van Q., Kantarjian H.M., Talpaz M., Aggarwal B.B. (2003) Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102 : 987 995.
44. Tyagi A., Singh R.P., Agarwal C., Siriwardana S., Sclafani R.A., Agarwal R. (2005) Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2- Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26 : 1978 1987.
45. Maga G., Hubscher U. (2008) Repair and translesion DNA polymerases as anticancer drug targets. Anticancer Agents Med Chem 8 : 431 447.
46. Palchaudhuri R., Hergenrother P.J. (2007) DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 18 : 497 503.
47. Zhu F.L., Zhou S.N., Vrijmoed L.L.P. (2004) Xanthone Derivatives Isolated from two Mangrove EndophyticFungi #2526 and #1850 from the South China Sea. Nat Prod Res Dev 16 : 406.
48. Froelich-Ammon S.J., Osheroff N. (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270 : 21429 21432.
49. Tosa H.I., Tanaka T., Nozaki H., Ikeda S., Tsutsui K., Tsutsui K., Yamada M., Fujimori S. (1997) Inhibitory Activity of Xanthone Derivatives Isolated from some Guttiferaeous Plants Against DNA Topoisomerases I and II. Chem Pharm Bull 45 : 418 420.
50. Permana P.A., Ho D.K., Cassady J.M., Snapka R.M. (1994) Mechanism of action of the antileukemic xanthone psorospermin: DNA strand breaks, abasic sites, and protein-DNA cross-links. Cancer Res 54 : 3191 3195.
51. Kwok Y., Hurley L.H. (1998) Topoisomerase II site-directed alkylation of DNA by psorospermin and its effect on topoisomerase II-mediated DNA cleavage. J Biol Chem 273 : 33020 33026. (Pubitemid 28557697)
52. Adams J.M., Cory S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281 : 1322 1326.
53. Fernandez-Luna J.L. (2008) Regulation of pro-apoptotic BH3-only proteins and its contribution to cancer progression and chemoresistance. Cell Signal 20 : 1921 1926.
54. Zha J., Harada H., Osipov K., Jockel J., Waksman G., Korsmeyer S.J. (1997) BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem 272 : 24101 24104.
55. Kang M.H., Reynolds C.P. (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15 : 1126 1132.
56. Lessene G., Czabotar P.E., Colman P.M. (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7 : 989 1000.
57. Yip K.W., Reed J.C. (2008) Bcl-2 family proteins and cancer. Oncogene 27 : 6398 6406.
58. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16 : 360 367.
59. Azmi A.S., Mohammad R.M. (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218 : 13 21.
60. Del Gaizo Moore V., Letai A. (2008) Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol 615 : 159 175.
61. Chauhan D., Velankar M., Brahmandam M., Hideshima T., Podar K., Richardson P., Schlossman R., Ghobrial I., Raje N., Munshi N., Anderson K.C. (2007) A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26 : 2374 2380.
62. Del Gaizo Moore V., Schlis K.D., Sallan S.E., Armstrong S.A., Letai A. (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111 : 2300 2309.